Clues to Disease Activity in Juvenile Dermatomyositis: Neopterin and Other Biomarkers

Easily accessible biomarkers are urgently needed to evaluate immune activation in Juvenile Dermatomyositis (JDM). The goal of this retrospective study is to define immunological and clinical differences between untreated JDM patients with either normal or elevated (>10 mmol/L) levels of neopterin, a biomarker of macrophage activation. We included all JDM with neopterin data obtained before initiating medical therapy. We assessed T, B, NK cell populations, muscle enzymes, and disease activity scores for skin (sDAS), muscle (mDAS), total (tDAS), the duration of untreated disease, disease course, and myositis-specific antibody (MSA). Seventy-nine percent of 139 untreated JDM patients had elevated serum neopterin. The group with elevated neopterin had significantly more active disease: tDAS 11.9 vs. 8.1 (p < 0.0001), mDAS 5.8 vs. 3.1 (p < 0.0001), sDAS 6.1 vs. 4.9 (p = 0.0002), aldolase 24.0 vs. 7.6 U/L (p < 0.0001), von Willebrand factor antigen (p < 0.0001), and ESR 19.8 vs. 11.5 mm/hr (p = 0.01). The flow cytometry documented both reduced T cells (1494 vs. 2278/mm3, p = 0.008) and NK cells (145 vs. 240/mm3, p = 0.003). TNFα-308AA/AG polymorphism was more common in children with elevated neopterin than TNFα-308GG (p 0.05). We conclude that the availability of neopterin data will contribute to the rapid assessment of untreated JDM disease activity.

[1]  L. Pachman,et al.  Transcriptomes of peripheral blood mononuclear cells from juvenile dermatomyositis patients show elevated inflammation even when clinically inactive , 2021, bioRxiv.

[2]  Z. Amoura,et al.  Elevated Neopterin Levels Predict Fatal Outcome in SARS-CoV-2-Infected Patients , 2021, Frontiers in Cellular and Infection Microbiology.

[3]  L. Pachman,et al.  Juvenile Dermatomyositis: New Clues to Diagnosis and Therapy , 2021, Current Treatment Options in Rheumatology.

[4]  Victoria Liu,et al.  Association of p155/140 Autoantibody With Loss of Nailfold Capillaries but not Generalized Lipodystrophy: A Study of Ninety‐Six Children With Juvenile Dermatomyositis , 2020, Arthritis care & research.

[5]  D. Cuadras,et al.  Cerebrospinal fluid neopterin as a biomarker of neuroinflammatory diseases , 2020, Scientific Reports.

[6]  Y. Hathout,et al.  Serum protein biomarkers for juvenile dermatomyositis: a pilot study , 2020, BMC Rheumatology.

[7]  S. Kamphuis,et al.  Endothelial and Inflammation Biomarker Profiles at Diagnosis Reflecting Clinical Heterogeneity and Serving as a Prognostic Tool for Treatment Response in Two Independent Cohorts of Patients With Juvenile Dermatomyositis , 2020, Arthritis & Rheumatology (Hoboken, N.j.).

[8]  Guochun Wang,et al.  A high level of serum neopterin is associated with rapidly progressive interstitial lung disease and reduced survival in dermatomyositis , 2019, Clinical and experimental immunology.

[9]  M. Viljoen,et al.  Comparison between plasma neopterin and the urine neopterin:creatinine ratio as inflammatory biomarkers , 2019, African health sciences.

[10]  K. Ohmura,et al.  Serum neopterin as well as ferritin, soluble interleukin-2 receptor, KL-6 and anti-MDA5 antibody titer provide markers of the response to therapy in patients with interstitial lung disease complicating anti-MDA5 antibody-positive dermatomyositis , 2019, Modern rheumatology.

[11]  E. Hoffman,et al.  Serum biomarkers of glucocorticoid response and safety in anti-neutrophil cytoplasmic antibody-associated vasculitis and juvenile dermatomyositis , 2018, Steroids.

[12]  L. Pachman,et al.  Advances in Juvenile Dermatomyositis: Myositis Specific Antibodies Aid in Understanding Disease Heterogeneity. , 2018, The Journal of pediatrics.

[13]  I. Lundberg,et al.  New Myositis Classification Criteria—What We Have Learned Since Bohan and Peter , 2018, Current Rheumatology Reports.

[14]  G. Shaddick,et al.  Autoantibodies in juvenile-onset myositis: Their diagnostic value and associated clinical phenotype in a large UK cohort , 2017, Journal of autoimmunity.

[15]  P. Szcześniak,et al.  Neopterin as a marker of cellular immunological response. , 2017, Postepy higieny i medycyny doswiadczalnej.

[16]  L. Pachman,et al.  Decreased CD3-CD16+CD56+ natural killer cell counts in children with orbital myositis: a clue to disease activity , 2017, RMD Open.

[17]  Chiang-Ching Huang,et al.  Pulmonary Function Tests in Idiopathic Inflammatory Myopathy: Association With Clinical Parameters in Children , 2013, Arthritis care & research.

[18]  L. Pachman,et al.  Serum Neopterin Levels as a Diagnostic Marker of Hemophagocytic Lymphohistiocytosis Syndrome , 2011, Clinical and Vaccine Immunology.

[19]  L. Pachman,et al.  Association of normal nailfold end row loop numbers with a shorter duration of untreated disease in children with juvenile dermatomyositis. , 2010, Arthritis and rheumatism.

[20]  A. Vallejo,et al.  Extranodal lymphoid microstructures in inflamed muscle and disease severity of new-onset juvenile dermatomyositis. , 2009, Arthritis and rheumatism.

[21]  J. Fahey,et al.  Serum neopterin, an immune activation marker, independently predicts disease progression in advanced HIV-1 infection. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  A. Dyer,et al.  Skin involvement in juvenile dermatomyositis is associated with loss of end row nailfold capillary loops. , 2004, The Journal of rheumatology.

[23]  A. Dyer,et al.  US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. , 2003, Arthritis and rheumatism.

[24]  T. Takken,et al.  The physiological and physical determinants of functional ability measures in children with juvenile dermatomyositis. , 2003, Rheumatology.

[25]  R. Bode,et al.  Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence. , 2003, Arthritis and rheumatism.

[26]  Christine A. Biron,et al.  Coordinated and Distinct Roles for IFN-αβ, IL-12, and IL-15 Regulation of NK Cell Responses to Viral Infection1 , 2002, The Journal of Immunology.

[27]  P. Lachenbruch,et al.  Neopterin and quinolinic acid are surrogate measures of disease activity in the juvenile idiopathic inflammatory myopathies. , 2002, Clinical chemistry.

[28]  L. Pachman,et al.  Expression of TNFα by muscle fibers in biopsies from children with untreated juvenile dermatomyositis : Association with the TNFα-308A allele , 2001 .

[29]  L. Pachman,et al.  Expression of TNFalpha by muscle fibers in biopsies from children with untreated juvenile dermatomyositis: association with the TNFalpha-308A allele. , 2001, Clinical immunology.

[30]  David E. Levy,et al.  Distinct Requirements for IFNs and STAT1 in NK Cell Function1 , 2000, The Journal of Immunology.

[31]  L. Pachman,et al.  TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications. , 2000, Arthritis and rheumatism.

[32]  C. Heusser,et al.  Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells , 1993, The Journal of experimental medicine.

[33]  A. Martini,et al.  Correlation of serum neopterin concentrations with disease activity in juvenile dermatomyositis. , 1993, Archives of disease in childhood.

[34]  A. Bohan,et al.  Polymyositis and dermatomyositis (second of two parts). , 1975, The New England journal of medicine.

[35]  A. Bohan,et al.  Polymyositis and dermatomyositis (second of two parts). , 1975 .